CoChat

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

Open access
Richter-Larrea, Jose A., Robles, Eloy F., Fresquet, Vicente, Beltran, Elena, Rullan, Antonio J., Agirre, Xabier, Calasanz, Maria José, Panizo, Carlos, Richter, Jose A., Hernandez, Jesus M., Roman-Gomez, Jose, Prosper, Felipe, Martinez-Climent, Jose A. · 2010 · Blood
Cited by 113

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

In Burkitt lymphoma/leukemia (BL), achievement of complete remission with first-line chemotherapy remains a challenging issue, as most patients who respond remain disease-free, whereas those refractory have few options of being rescued with salvage therapies. The mechanisms underlying BL chemoresistance and how it can be circumvented remain undetermined. We previously reported the frequent inactivation of the proapoptotic BIM gene in B-cell lymphomas. Here we show that BIM epigenetic silencing by concurrent promoter hypermethylation and deacetylation occurs frequently in primary BL samples and BL-derived cell lines. Remarkably, patients with BL with hypermethylated BIM presented lower complete remission rate (24% vs 79%; P = .002) and shorter overall survival (P = .007) than those with BIM-expressing lymphomas, indicating that BIM transcriptional repression may mediate tumor chemoresistance. Accordingly, by combining in vitro and in vivo studies of human BL-xenografts grown in immunodeficient RAG2−/−γc−/− mice and of murine B220+IgM+ B-cell lymphomas generated in Eμ-MYC and Eμ-MYC-BIM+/− transgenes, we demonstrate that lymphoma chemoresistance is dictated by BIM gene dosage and is reversible on BIM reactivation by genetic manipulation or after treatment with histone-deacetylase inhibitors. We suggest that the combination of histone-deacetylase inhibitors and high-dose chemotherapy may overcome chemoresistance, achieve durable remission, and improve survival of patients with BL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-02-268003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 113

Metadata

Authors
Richter-Larrea, J. A., Robles, E. F., Fresquet, V., Beltran, E., Rullan, A. J., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. A., Hernandez, J. M., Roman-Gomez, J., Prosper, F., & Martinez-Climent, J. A.
Venue
Blood
Published
2010-10-07
Volume
116
Issue
14
Pages
2531-2542
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1968948902
Cited by
113
References
4
FWCI
6.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. https://app.cochat.ai/papers/10.1182/blood-2010-02-268003
The paper
Richter-Larrea, J. A., Robles, E. F., Fresquet, V., Beltran, E., Rullan, A. J., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. A., Hernandez, J. M., Roman-Gomez, J., Prosper, F., & Martinez-Climent, J. A. (2010). Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood. https://doi.org/10.1182/blood-2010-02-268003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.